Home > References - Stroke Prevention in Atrial...

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

Lopes RD, Crowley MJ, Shah BR, et al. Stroke Prevention in Atrial Fibrillation [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Aug. (Comparative Effectiveness Reviews, No. 123.)

  • This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

References

1.
Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114(7):e257–354. [PubMed: 16908781]
2.
Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285(18):2370–5. [PubMed: 11343485]
3.
Furberg CD, Psaty BM, Manolio TA, et al. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study) Am J Cardiol. 1994;74(3):236–41. [PubMed: 8037127]
4.
Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics—2010 update: a report from the American Heart Association. Circulation. 2010;121(7):e46–e215. [PubMed: 20019324]
5.
Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114(2):119–25. [PubMed: 16818816]
6.
Lee WC, Lamas GA, Balu S, et al. Direct treatment cost of atrial fibrillation in the elderly American population: a Medicare perspective. J Med Econ. 2008;11(2):281–98. [PubMed: 19450086]
7.
Thrall G, Lane D, Carroll D, et al. Quality of life in patients with atrial fibrillation: a systematic review. Am J Med. 2006;119(5):448.e1–19. [PubMed: 16651058]
8.
Stewart S, Hart CL, Hole DJ, et al. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med. 2002;113(5):359–64. [PubMed: 12401529]
9.
Dulli DA, Stanko H, Levine RL. Atrial fibrillation is associated with severe acute ischemic stroke. Neuroepidemiology. 2003;22(2):118–23. [PubMed: 12629277]
10.
Lin HJ, Wolf PA, Kelly-Hayes M, et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke. 1996;27(10):1760–4. [PubMed: 8841325]
11.
Paciaroni M, Agnelli G, Caso V, et al. Atrial fibrillation in patients with first-ever stroke: frequency, antithrombotic treatment before the event and effect on clinical outcome. J Thromb Haemost. 2005;3(6):1218–23. [PubMed: 15892862]
12.
Caro JJ. An economic model of stroke in atrial fibrillation: the cost of suboptimal oral anticoagulation. Am J Manag Care. 2004;10(14 Suppl):S451–58. discussion S8–61. [PubMed: 15696909]
13.
Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285(22):2864–70. [PubMed: 11401607]
14.
Inoue H, Nozawa T, Hirai T, et al. Accumulation of risk factors increases risk of thromboembolic events in patients with nonvalvular atrial fibrillation. Circ J. 2006;70(6):651–6. [PubMed: 16723782]
15.
Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263–72. [PubMed: 19762550]
16.
Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093–100. [PubMed: 20299623]
17.
Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Eur Heart J. 2010;31(19):2369–429. [PubMed: 20802247]
18.
Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest. 2008;133(6 Suppl):160S–98S. [PubMed: 18574265]
19.
Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–67. [PubMed: 17577005]
20.
Hart RG, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999;131(7):492–501. [PubMed: 10507957]
21.
Gitter MJ, Jaeger TM, Petterson TM, et al. Bleeding and thromboembolism during anticoagulant therapy: a population-based study in Rochester, Minnesota. Mayo Clin Proc. 1995;70(8):725–33. [PubMed: 7630209]
22.
Hylek EM, Evans-Molina C, Shea C, et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007;115(21):2689–96. [PubMed: 17515465]
23.
Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest. 2008;133(6 Suppl):546S–92S. [PubMed: 18574273]
24.
Estes NA 3rd, Halperin JL, Calkins H, et al. ACC/AHA/Physician Consortium 2008 clinical performance measures for adults with nonvalvular atrial fibrillation or atrial flutter: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and the Physician Consortium for Performance Improvement (Writing Committee to Develop Clinical Performance Measures for Atrial Fibrillation): developed in collaboration with the Heart Rhythm Society. Circulation. 2008;117(8):1101–20. [PubMed: 18283199]
25.
Birman-Deych E, Radford MJ, Nilasena DS, et al. Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation. Stroke. 2006;37(4):1070–4. [PubMed: 16528001]
26.
Piccini JP, Hernandez AF, Zhao X, et al. Quality of care for atrial fibrillation among patients hospitalized for heart failure. J Am Coll Cardiol. 2009;54(14):1280–9. [PubMed: 19778670]
27.
Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51. [PubMed: 19717844]
28.
Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91. [PubMed: 21830957]
29.
Lopes RD, Alexander JH, Al-Khatib SM, et al. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J. 2010;159(3):331–9. [PubMed: 20211292]
30.
Lip GY, Andreotti F, Fauchier L, et al. Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. Europace. 2011;13(5):723–46. [PubMed: 21515596]
31.
Douketis JD, Berger PB, Dunn AS, et al. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest. 2008;133(6 Suppl):299S–339S. [PubMed: 18574269]
32.
Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med. 1997;336(21):1506–11. [PubMed: 9154771]
33.
Siegal D, Yudin J, Kaatz S, et al. Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation. 2012;126(13):1630–9. [PubMed: 22912386]
34.
Spyropoulos AC. Bridging therapy and oral anticoagulation: current and future prospects. Curr Opin Hematol. 2010;17(5):444–9. [PubMed: 20613508]
35.
Agency for Healthcare Research and Quality. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. Rockville, MD: Agency for Healthcare Research and Quality; [Accessed May 7, 2012]. Available at: www​.effectivehealthcare​.ahrq.gov/index.cfm​/search-for-guides-reviews-and-reports​/?pageaction=displayproduct&productid=318.
36.
Agency for Healthcare Research and Quality. Methods Guide for Medical Test Reviews. Rockville, MD: Agency for Healthcare Research and Quality; [Accessed May 30, 2012]. Available at: www​.effectivehealthcare​.ahrq.gov/index.cfm​/search-for-guides-reviews-and-reports​/?productid=558&pageaction​=displayproduct.
37.
Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. [PMC free article: PMC2707599] [PubMed: 19621072]
38.
Evidence-based Practice Center Systematic Review Protocol. Project Title: Stroke Prevention in Atrial Fibrillation. Jan 30, 2012. [Accessed June 21, 2012]. Available at: www​.effectivehealthcare​.ahrq.gov/index.cfm​/search-for-guides-reviews-and-reports​/?pageaction=displayproduct&productid=947.
39.
Adam SS, McDuffie JR, Ortel T. Comparative Effectiveness of Warfarin and New Oral Anticoagulants for the Management of Atrial Fibrillation and Venous Thromboembolism: A Systematic Review. Ann Intern Med. 2012 [PubMed: 22928173]
40.
Agarwal S, Hachamovitch R, Menon V. Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis. Arch Intern Med. 2012;172(8):623–31. discussion 31–3. [PubMed: 22450212]
41.
Aguilar M, Hart R. Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 2005;(4):CD001925. [PubMed: 16235290]
42.
Aguilar MI, Hart R, Pearce LA. Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 2007;(3):CD006186. [PubMed: 17636831]
43.
Akins PT, Feldman HA, Zoble RG, et al. Secondary stroke prevention with ximelagatran versus warfarin in patients with atrial fibrillation: pooled analysis of SPORTIF III and V clinical trials. Stroke. 2007;38(3):874–80. [PubMed: 17255547]
44.
Alam T, Clyne CA, White CM. Pharmacologic and nonpharmacologic thromboprophylactic strategies in atrial fibrillation. Journal of Comparative Effectiveness Research. 2012;1(3):225–39. [PubMed: 24237406]
45.
Andersen LV, Vestergaard P, Deichgraeber P, et al. Warfarin for the prevention of systemic embolism in patients with non-valvular atrial fibrillation: a meta-analysis. Heart. 2008;94(12):1607–13. [PubMed: 18208828]
46.
Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation. Stroke. 2008;39(6):1901–10. [PubMed: 18420954]
47.
Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology. 2007;69(6):546–54. [PubMed: 17679673]
48.
Ansara AJ, Nisly SA, Arif SA, et al. Aspirin dosing for the prevention and treatment of ischemic stroke: an indication-specific review of the literature. Ann Pharmacother. 2010;44(5):851–62. [PubMed: 20388864]
49.
Baker WL, Phung O. Systematic Review and Adjusted Indirect Comparison Meta-Analysis of Oral Anticoagulants in Atrial Fibrillation. Circ Cardiovasc Qual Outcomes. 2012:1–9. [PubMed: 22912382]
50.
Banerjee A, Marin F, Lip GY. A new landscape for stroke prevention in atrial fibrillation: focus on new anticoagulants, antiarrhythmic drugs, and devices. Stroke. 2011;42(11):3316–22. [PubMed: 21998051]
51.
Berge E, Sandercock P. Anticoagulants versus antiplatelet agents for acute ischaemic stroke. Cochrane Database Syst Rev. 2002;(4):CD003242. [PubMed: 12519590]
52.
Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation * Developed with the special contribution of the European Heart Rhythm Association. Europace. 2012;14(10):1385–413. [PubMed: 22923145]
53.
Capodanno D, Capranzano P, Giacchi G, et al. Novel oral anticoagulants versus warfarin in non-valvular atrial fibrillation: A meta-analysis of 50,578 patients. Int J Cardiol. 2012 [PubMed: 22494863]
54.
Chen WT, White CM, Phung OJ, et al. Association between CHADSrisk factors and anticoagulation-related bleeding: a systematic literature review. Mayo Clin Proc. 2011;86(6):509–21. [PMC free article: PMC3104910] [PubMed: 21628615]
55.
Cleland JG, Shelton R, Nikitin N, et al. Prevalence of markers of heart failure in patients with atrial fibrillation and the effects of ximelagatran compared to warfarin on the incidence of morbid and fatal events: a report from the SPORTIF III and V trials. Eur J Heart Fail. 2007;9(6–7):730–9. [PubMed: 17360232]
56.
Coleman CI, Sobieraj DM, Winkler S, et al. Effect of pharmacological therapies for stroke prevention on major gastrointestinal bleeding in patients with atrial fibrillation. Int J Clin Pract. 2011 [PubMed: 22093613]
57.
Coleman CI, Sobieraj DM, Winkler S, et al. Effect of pharmacological therapies for stroke prevention on major gastrointestinal bleeding in patients with atrial fibrillation. Int J Clin Pract. 2012;66(1):53–63. [PubMed: 22093613]
58.
Cooper NJ, Sutton AJ, Lu G, et al. Mixed comparison of stroke prevention treatments in individuals with nonrheumatic atrial fibrillation. Arch Intern Med. 2006;166(12):1269–75. [PubMed: 16801509]
59.
Dentali F, Douketis JD, Lim W, et al. Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: a meta-analysis of randomized trials. Arch Intern Med. 2007;167(2):117–24. [PubMed: 17242311]
60.
Deshmukh A, Hilleman DE, Del Core M, et al. Antithrombotic Regimens in Patients With Indication for Long-Term Anticoagulation Undergoing Coronary Interventions-Systematic Analysis, Review of Literature, and Implications on Management. Am J Ther. 2011 [PubMed: 21519218]
61.
Engelbertz C, Reinecke H. Atrial fibrillation and oral anticoagulation in chronic kidney disease. Journal of Atrial Fibrillation. 2012;2(10)
62.
Fuster V, Ryden LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol. 2011;57(11):e101–98. [PubMed: 21392637]
63.
Garcia DA, Granger CB. Anticoagulation, novel agents, and procedures: Can we pardon the interruption? Circulation. 2012;126(3):255–7. [PubMed: 22700855]
64.
Goldstein LB, Adams R, Alberts MJ, et al. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2006;113(24):e873–923. [PubMed: 16785347]
65.
Harenberg J, Marx S, Diener HC, et al. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network metaanalysis. Int Angiol. 2012;31(4):330–9. [PubMed: 22801398]
66.
Hermosillo AJ, Spinler SA. Aspirin, clopidogrel, and warfarin: is the combination appropriate and effective or inappropriate and too dangerous? Ann Pharmacother. 2008;42(6):790–805. [PubMed: 18477734]
67.
Hughes M, Lip GY. Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: a systematic review. QJM. 2007;100(10):599–607. [PubMed: 17846060]
68.
Hughes M, Lip GY. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost. 2008;99(2):295–304. [PubMed: 18278178]
69.
Keogh C, Wallace E, Dillon C, et al. Validation of the CHADS2 clinical prediction rule to predict ischaemic stroke. A systematic review and meta-analysis. Thromb Haemost. 2011;106(3):528–38. [PubMed: 21800003]
70.
Knecht S, Wilton SB, Haissaguerre M. The 2010 update of the ESC guidelines for the management of atrial fibrillation. Circ J. 2010;74(12):2534–7. [PubMed: 21060205]
71.
Komócsi A, Vorobcsuk A, Kehl D, Aradi D. Use of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome: Systematic review and meta-analysis of randomized controlled trials. Arch Intern Med. 2012:1–9. [PubMed: 23007264]
72.
Lip GY, Edwards SJ. Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. Thromb Res. 2006;118(3):321–33. [PubMed: 16198396]
73.
Lip GY, Larsen TB, Skjoth F, et al. Indirect Comparisons of New Oral Anticoagulant Drugs for Efficacy and Safety When Used for Stroke Prevention in Atrial Fibrillation. J Am Coll Cardiol. 2012 [PubMed: 22575324]
74.
Liu T, Korantzopoulos P, Li L, et al. Survival benefit of new anticoagulants compared with warfarin in patients with atrial fibrillation: A meta-analysis. Int J Cardiol. 2012;156(1):96–7. [PubMed: 22257690]
75.
Loewen P, Dahri K. Risk of bleeding with oral anticoagulants: an updated systematic review and performance analysis of clinical prediction rules. Ann Hematol. 2011;90(10):1191–200. [PubMed: 21670974]
76.
Mantha S, Ansell J. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. Thromb Haemost. 2012;108(3) [PubMed: 22740145]
77.
Miller CS, Grandi SM, Shimony A, et al. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol. 2012;110(3):453–60. [PubMed: 22537354]
78.
Munkholm-Larsen S, Cao C, Yan TD, et al. Percutaneous atrial appendage occlusion for stroke prevention in patients with atrial fibrillation: a systematic review. Heart. 2012;98(12):900–7. [PubMed: 22511532]
79.
Ogilvie IM, Welner SA, Cowell W, et al. Ischaemic stroke and bleeding rates in ‘real-world’ atrial fibrillation patients. Thromb Haemost. 2011;106(1):34–44. [PubMed: 21614409]
80.
Owen A. Antithrombotic treatment for the primary prevention of stroke in patients with non valvular atrial fibrillation: a reappraisal of the evidence and network meta analysis. Int J Cardiol. 2010;142(3):218–23. [PubMed: 20061035]
81.
Pisters R, Lane DA, Marin F, et al. Stroke and thromboembolism in atrial fibrillation. Circ J. 2012;76(10):2289–304. [PubMed: 23001018]
82.
Potpara TS, Polovina MM, Licina MM, et al. Novel Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: Focus on Apixaban. Adv Ther. 2012 [PubMed: 22684583]
83.
Prom R, Spinler SA. The role of apixaban for venous and arterial thromboembolic disease. Ann Pharmacother. 2011;45(10):1262–83. [PubMed: 21954450]
84.
Roskell NS, Lip GY, Noack H, et al. Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate. Thromb Haemost. 2010;104(6):1106–15. [PubMed: 20967400]
85.
Santangeli P, Di Biase L, Horton R, et al. Ablation of atrial fibrillation under therapeutic warfarin reduces periprocedural complications: evidence from a meta-analysis. Circ Arrhythm Electrophysiol. 2012;5(2):302–11. [PubMed: 22271713]
86.
Saxena R, Koudstaal P. Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attack. Cochrane Database Syst Rev. 2004;(4):CD000187. [PubMed: 15494992]
87.
Saxena R, Koudstaal PJ. Anticoagulants for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischaemic attack. Cochrane Database Syst Rev. 2004;(2):CD000185. [PubMed: 15106146]
88.
Schmitt J, Duray G, Gersh BJ, et al. Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. Eur Heart J. 2009;30(9):1038–45. [PubMed: 19109347]
89.
Schneeweiss S, Gagne JJ, Patrick AR, et al. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2012;5(4):480–6. [PMC free article: PMC3471365] [PubMed: 22787066]
90.
Skanes AC, Healey JS, Cairns JA, et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol. 2012;28(2):125–36. [PubMed: 22433576]
91.
Spyropoulos AC, Bauersachs RM, Omran H, et al. Periprocedural bridging therapy in patients receiving chronic oral anticoagulation therapy. Curr Med Res Opin. 2006;22(6):1109–22. [PubMed: 16846544]
92.
Testa L, Andreotti F, Biondi Zoccai GG, et al. Ximelagatran/melagatran against conventional anticoagulation: a meta-analysis based on 22,639 patients. Int J Cardiol. 2007;122(2):117–24. [PubMed: 17222926]
93.
Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med. 2012;172(5):397–402. [PubMed: 22231617]
94.
van Walraven C, Hart RG, Connolly S, et al. Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. Stroke. 2009;40(4):1410–6. [PubMed: 19182090]
95.
Whiting PF, Rutjes AWS, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):529–36. [PubMed: 22007046]
96.
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88. [PubMed: 3802833]
97.
Ohman EM, Granger CB, Harrington RA, et al. Risk stratification and therapeutic decision making in acute coronary syndromes. JAMA. 2000;284(7):876–8. [PubMed: 10938178]
98.
Owens DK, Lohr KN, Atkins D, et al. AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions-Agency for Healthcare Research and Quality and the Effective Health Care Program. J Clin Epidemiol. 2010;63(5):513–23. [PubMed: 19595577]
99.
Schunemann HJ, Oxman AD, Brozek J, et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ. 2008;336(7653):1106–10. [PMC free article: PMC2386626] [PubMed: 18483053]
100.
Atkins D, Chang SM, Gartlehner G, et al. Assessing applicability when comparing medical interventions: AHRQ and the Effective Health Care Program. J Clin Epidemiol. 2011;64(11):1198–207. [PubMed: 21463926]
101.
Alberts M, Amatangelo M, Bauer KA, et al. Consensus Statement on Appropriate Anticoagulant Use. Atrial Fibrillation Optimal Treatment Task Force; 2012. [Accessed November 19, 2012]. Assessing Stroke and Bleeding Risk in Atrial Fibrillation. Available at: www​.agingresearch.org​/section/topic/atrialfibrillation​/consensusstatement.
102.
Olesen JB, Lip GY, Lindhardsen J, et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a ‘real world’ nationwide cohort study. Thromb Haemost. 2011;106(4):739–49. [PubMed: 21789337]
103.
Poli D, Testa S, Antonucci E, et al. Bleeding and stroke risk in a real-world prospective primary prevention cohort of patients with atrial fibrillation. Chest. 2011;140(4):918–24. [PMC free article: PMC3734882] [PubMed: 21511826]
104.
Olesen JB, Lip GY, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011;342:d124. [PMC free article: PMC3031123] [PubMed: 21282258]
105.
Van Staa TP, Setakis E, Di Tanna GL, et al. A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice. J Thromb Haemost. 2011;9(1):39–48. [PubMed: 21029359]
106.
Sadanaga T, Kohsaka S, Ogawa S. D-dimer levels in combination with clinical risk factors can effectively predict subsequent thromboembolic events in patients with atrial fibrillation during oral anticoagulant therapy. Cardiology. 2010;117(1):31–6. [PubMed: 20881392]
107.
Ad N, Henry L, Schlauch K, et al. The CHADS score role in managing anticoagulation after surgical ablation for atrial fibrillation. Ann Thorac Surg. 2010;90(4):1257–62. [PubMed: 20868824]
108.
Beinart R, Heist EK, Newell JB, et al. Left atrial appendage dimensions predict the risk of stroke/TIA in patients with atrial fibrillation. J Cardiovasc Electrophysiol. 2011;22(1):10–5. [PubMed: 20662984]
109.
Poli D, Lip GY, Antonucci E, et al. Stroke risk stratification in a “real-world” elderly anticoagulated atrial fibrillation population. J Cardiovasc Electrophysiol. 2011;22(1):25–30. [PubMed: 20653814]
110.
Ruiz Ortiz M, Romo E, Mesa D, et al. Oral anticoagulation in nonvalvular atrial fibrillation in clinical practice: impact of CHADS(2) score on outcome. Cardiology. 2010;115(3):200–4. [PubMed: 20160440]
111.
Nair CK, Holmberg MJ, Aronow WS, et al. Thromboembolism in patients with atrial fibrillation with and without left atrial thrombus documented by transesophageal echocardiography. Am J Ther. 2009;16(5):385–92. [PubMed: 19955857]
112.
Crandall MA, Horne BD, Day JD, et al. Atrial fibrillation significantly increases total mortality and stroke risk beyond that conveyed by the CHADS2 risk factors. Pacing Clin Electrophysiol. 2009;32(8):981–6. [PubMed: 19659615]
113.
Masaki N, Suzuki M, Iwatsuka R, et al. Effectiveness of risk stratification according to CHADS2 score in Japanese patients with nonvalvular atrial fibrillation. Int Heart J. 2009;50(3):323–9. [PubMed: 19506336]
114.
Poli D, Antonucci E, Grifoni E, et al. Stroke risk in atrial fibrillation patients on warfarin. Predictive ability of risk stratification schemes for primary and secondary prevention. Thromb Haemost. 2009;101(2):367–72. [PubMed: 19190823]
115.
Morgan CL, McEwan P, Tukiendorf A, et al. Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control. Thromb Res. 2009;124(1):37–41. [PubMed: 19062079]
116.
Rietbrock S, Heeley E, Plumb J, et al. Chronic atrial fibrillation: Incidence, prevalence, and prediction of stroke using the Congestive heart failure, Hypertension, Age >75, Diabetes mellitus, and prior Stroke or transient ischemic attack (CHADS2) risk stratification scheme. Am Heart J. 2008;156(1):57–64. [PubMed: 18585497]
117.
Okuyama H, Hirono O, Tamura H, et al. Usefulness of intensity variation in the left atrial appendage with contrast echocardiography to predict ischemic stroke recurrence in patients with atrial fibrillation. Am J Cardiol. 2008;101(11):1630–7. [PubMed: 18489942]
118.
Fang MC, Go AS, Chang Y, et al. Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. J Am Coll Cardiol. 2008;51(8):810–5. [PMC free article: PMC3534960] [PubMed: 18294564]
119.
Baruch L, Gage BF, Horrow J, et al. Can patients at elevated risk of stroke treated with anticoagulants be further risk stratified? Stroke. 2007;38(9):2459–63. [PubMed: 17673721]
120.
Stollberger C, Chnupa P, Abzieher C, et al. Mortality and rate of stroke or embolism in atrial fibrillation during long-term follow-up in the embolism in left atrial thrombi (ELAT) study. Clin Cardiol. 2004;27(1):40–6. [PubMed: 14743856]
121.
Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003;349(11):1019–26. [PubMed: 12968085]
122.
Wang TJ, Massaro JM, Levy D, et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA. 2003;290(8):1049–56. [PubMed: 12941677]
123.
Stoddard MF, Singh P, Dawn B, et al. Left atrial thrombus predicts transient ischemic attack in patients with atrial fibrillation. Am Heart J. 2003;145(4):676–82. [PubMed: 12679765]
124.
Miyazaki S, Ito T, Suwa M, et al. Role of transesophageal echocardiography in the prediction of thromboembolism in patients with chronic nonvalvular atrial fibrillation. Jpn Circ J. 2001;65(10):874–8. [PubMed: 11665791]
125.
Lind M, Fahlen M, Kosiborod M, et al. Variability of INR and its relationship with mortality, stroke, bleeding and hospitalisations in patients with atrial fibrillation. Thromb Res. 2012;129(1):32–5. [PubMed: 21851969]
126.
Ruiz-Nodar JM, Marin F, Manzano-Fernandez S, et al. An evaluation of the CHADS2 stroke risk score in patients with atrial fibrillation who undergo percutaneous coronary revascularization. Chest. 2011;139(6):1402–9. [PubMed: 20864616]
127.
Komatsu T, Tachibana H, Sato Y, et al. Relationship between CHADS2 score and ischemic stroke during rhythm control therapy for paroxysmal atrial fibrillation. Int Heart J. 2010;51(1):24–9. [PubMed: 20145347]
128.
Ruiz Ortiz M, Romo E, Mesa D, et al. [Predicting embolic events in patients with nonvalvular atrial fibrillation: evaluation of the CHADS2 score in a Mediterranean population]. Rev Esp Cardiol. 2008;61(1):29–35. [PubMed: 18221688]
129.
Olesen JB, Torp-Pedersen C, Hansen ML, et al. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0–1: A nationwide cohort study. Thromb Haemost. 2012;107(6):1172–9. [PubMed: 22473219]
130.
Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012;33(12):1500–10. [PubMed: 22246443]
131.
Naganuma M, Shiga T, Sato K, et al. Clinical outcome in Japanese elderly patients with non-valvular atrial fibrillation taking warfarin: a single-center observational study. Thromb Res. 2012;130(1):21–6. [PubMed: 22137743]
132.
Olesen JB, Lip GY, Lane DA, et al. Vascular disease and stroke risk in atrial fibrillation: a nationwide cohort study. Am J Med. 2012;125(8):826 e13–23. [PubMed: 22579139]
133.
Tamura H, Watanabe T, Nishiyama S, et al. Prognostic value of low left atrial appendage wall velocity in patients with ischemic stroke and atrial fibrillation. J Am Soc Echocardiogr. 2012;25(5):576–83. [PubMed: 22326133]
134.
Ruiz-Nodar JM, Marin F, Roldan V, et al. Should We Recommend Oral Anticoagulation Therapy in Patients With Atrial Fibrillation Undergoing Coronary Artery Stenting With a High HAS-BLED Bleeding Risk Score? Circ Cardiovasc Interv. 2012;5(4):459–66. [PubMed: 22787018]
135.
Potpara TS, Polovina MM, Licina MM, et al. Reliable identification of “truly low” thromboembolic risk in patients initially diagnosed with “lone” atrial fibrillation: the Belgrade atrial fibrillation study. Circ Arrhythm Electrophysiol. 2012;5(2):319–26. [PubMed: 22319004]
136.
Olesen JB, Fauchier L, Lane DA, et al. Risk factors for stroke and thromboembolism in relation to age among patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. Chest. 2012;141(1):147–53. [PubMed: 21680645]
137.
Fang MC, Go AS, Chang Y, et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol. 2011;58(4):395–401. [PMC free article: PMC3175766] [PubMed: 21757117]
138.
Lip GY, Frison L, Halperin JL, et al. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol. 2011;57(2):173–80. [PubMed: 21111555]
139.
Shireman TI, Mahnken JD, Howard PA, et al. Development of a contemporary bleeding risk model for elderly warfarin recipients. Chest. 2006;130(5):1390–6. [PubMed: 17099015]
140.
Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF) Am Heart J. 2006;151(3):713–9. [PubMed: 16504638]
141.
Aspinall SL, DeSanzo BE, Trilli LE, et al. Bleeding Risk Index in an anticoagulation clinic. Assessment by indication and implications for care. J Gen Intern Med. 2005;20(11):1008–13. [PMC free article: PMC1490253] [PubMed: 16307625]
142.
Olesen JB, Lip GYH, Hansen PR, et al. Bleeding risk in ‘real world’ patients with atrial fibrillation: Comparison of two established bleeding prediction schemes in a nationwide cohort. Journal of Thrombosis and Haemostasis. 2011;9(8):1460–7. [PubMed: 21624047]
143.
Apostolakis S, Lane DA, Guo Y, et al. Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED Bleeding Risk-Prediction Scores in Patients With Atrial Fibrillation Undergoing Anticoagulation: The AMADEUS (Evaluating the Use of SR34006 Compared to Warfarin or Acenocoumarol in Patients With Atrial Fibrillation) Study. J Am Coll Cardiol. 2012 [PubMed: 22858389]
144.
Gallego P, Roldan V, Torregrosa JM, et al. Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation. Circ Arrhythm Electrophysiol. 2012;5(2):312–8. [PubMed: 22319005]
145.
Roldan V, Marin F, Fernandez H, et al. Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a ‘real world’ anticoagulated atrial fibrillation population. Chest. 2012 [PubMed: 22722228]
146.
Lip GY, Banerjee A, Lagrenade I, et al. Assessing the Risk of Bleeding in Patients with Atrial Fibrillation: The Loire Valley Atrial Fibrillation Project. Circ Arrhythm Electrophysiol. 2012 [PubMed: 22923275]
147.
Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation. 2007;115(7):928–35. [PubMed: 17309939]
148.
Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med. 1998;105(2):91–9. [PubMed: 9727814]
149.
Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692–4. [PubMed: 15842354]
150.
Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92. [PubMed: 21870978]
151.
Ogawa S, Shinohara Y, Kanmuri K. Safety and efficacy of the oral direct factor xa inhibitor apixaban in Japanese patients with non-valvular atrial fibrillation. -The ARISTOTLE-J study. Circ J. 2011;75(8):1852–9. [PubMed: 21670542]
152.
Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806–17. [PubMed: 21309657]
153.
Hansen ML, Sorensen R, Clausen MT, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010;170(16):1433–41. [PubMed: 20837828]
154.
Weitz JI, Connolly SJ, Patel I, et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost. 2010;104(3):633–41. [PubMed: 20694273]
155.
Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet. 2009;374(9689):534–42. [PubMed: 19683639]
156.
Connolly SJ, Pogue J, Hart RG, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009;360(20):2066–78. [PubMed: 19336502]
157.
Doucet J, Greboval-Furstenfeld E, Tavildari A, et al. Which parameters differ in very old patients with chronic atrial fibrillation treated by anticoagulant or aspirin? Antithrombotic treatment of atrial fibrillation in the elderly. Fundam Clin Pharmacol. 2008;22(5):569–74. [PubMed: 18844728]
158.
Hart RG, Bhatt DL, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of stroke in patients with a history of atrial fibrillation: subgroup analysis of the CHARISMA randomized trial. Cerebrovasc Dis. 2008;25(4):344–7. [PubMed: 18303254]
159.
Bousser MG, Bouthier J, Buller HR, et al. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. Lancet. 2008;371(9609):315–21. [PubMed: 18294998]
160.
Ezekowitz MD, Reilly PA, Nehmiz G, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study) Am J Cardiol. 2007;100(9):1419–26. [PubMed: 17950801]
161.
Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007;370(9586):493–503. [PubMed: 17693178]
162.
Burton C, Isles C, Norrie J, et al. The safety and adequacy of antithrombotic therapy for atrial fibrillation: a regional cohort study. Br J Gen Pract. 2006;56(530):697–702. [PMC free article: PMC1876637] [PubMed: 16954003]
163.
Connolly S, Pogue J, Hart R, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367(9526):1903–12. [PubMed: 16765759]
164.
Tentschert S, Parigger S, Dorda V, et al. Recurrent vascular events in patients with ischemic stroke/TIA and atrial fibrillation in relation to secondary prevention at hospital discharge. Wien Klin Wochenschr. 2004;116(24):834–8. [PubMed: 15690967]
165.
Shireman TI, Howard PA, Kresowik TF, et al. Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients. Stroke. 2004;35(10):2362–7. [PubMed: 15331796]
166.
Stellbrink C, Nixdorff U, Hofmann T, et al. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial. Circulation. 2004;109(8):997–1003. [PubMed: 14967716]
167.
Yamaguchi T. Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation : a multicenter, prospective, randomized trial. Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group. Stroke. 2000;31(4):817–21. [PubMed: 10753981]
168.
Berge E, Abdelnoor M, Nakstad PH, et al. Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. Lancet. 2000;355(9211):1205–10. [PubMed: 10770301]
169.
Azoulay L, Dell’aniello S, Simon TA, et al. A net clinical benefit analysis of warfarin and aspirin on stroke in patients with atrial fibrillation: a nested case-control study. BMC Cardiovasc Disord. 2012;12(1):49. [PMC free article: PMC3444325] [PubMed: 22734842]
170.
Fosbol EL, Wang TY, Li S, et al. Safety and effectiveness of antithrombotic strategies in older adult patients with atrial fibrillation and non-ST elevation myocardial infarction. Am Heart J. 2012;163(4):720–8. [PubMed: 22520540]
171.
Hori M, Matsumoto M, Tanahashi N, et al. Rivaroxaban vs. Warfarin in Japanese Patients With Atrial Fibrillation. Circ J. 2012 [PubMed: 22664783]
172.
Yamashita T, Koretsune Y, Yasaka M, et al. Randomized, Multicenter, Warfarin-Controlled Phase II Study of Edoxaban in Japanese Patients With Non-Valvular Atrial Fibrillation. Circ J. 2012;76(8):1840–7. [PubMed: 22664798]
173.
Gao F, Zhou YJ, Wang ZJ, et al. Comparison of different antithrombotic regimens for patients with atrial fibrillation undergoing drug-eluting stent implantation. Circ J. 2010;74(4):701–8. [PubMed: 20208381]
174.
Lee BH, Park JS, Park JH, et al. The effect and safety of the antithrombotic therapies in patients with atrial fibrillation and CHADS score 1. J Cardiovasc Electrophysiol. 2010;21(5):501–7. [PubMed: 20021521]
175.
Jacobs LG, Billett HH, Freeman K, et al. Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: a single-center, retrospective, observational study. Am J Geriatr Pharmacother. 2009;7(3):159–66. [PubMed: 19616184]
176.
Rash A, Downes T, Portner R, et al. A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO) Age Ageing. 2007;36(2):151–6. [PubMed: 17175564]
177.
Vemmos KN, Tsivgoulis G, Spengos K, et al. Primary prevention of arterial thromboembolism in the oldest old with atrial fibrillation--a randomized pilot trial comparing adjusted-dose and fixed low-dose coumadin with aspirin. Eur J Intern Med. 2006;17(1):48–52. [PubMed: 16378886]
178.
Vemmos KN, Tsivgoulis G, Spengos K, et al. Anticoagulation influences long-term outcome in patients with nonvalvular atrial fibrillation and severe ischemic stroke. Am J Geriatr Pharmacother. 2004;2(4):265–73. [PubMed: 15903285]
179.
Tsivgoulis G, Spengos K, Zakopoulos N, et al. Efficacy of anticoagulation for secondary stroke prevention in older people with non-valvular atrial fibrillation: a prospective case series study. Age Ageing. 2005;34(1):35–40. [PubMed: 15591481]
180.
Lorenzoni R, Lazzerini G, Cocci F, et al. Short-term prevention of thromboembolic complications in patients with atrial fibrillation with aspirin plus clopidogrel: the Clopidogrel-Aspirin Atrial Fibrillation (CLAAF) pilot study. Am Heart J. 2004;148(1):e6. [PubMed: 15215815]
181.
Yigit Z, Kucukoglu MS, Okcun B, et al. The safety of low-molecular weight heparins for the prevention of thromboembolic events after cardioversion of atrial fibrillation. Jpn Heart J. 2003;44(3):369–77. [PubMed: 12825804]
182.
Frost L, Johnsen SP, Pedersen L, et al. Atrial fibrillation or flutter and stroke: a Danish population-based study of the effectiveness of oral anticoagulation in clinical practice. J Intern Med. 2002;252(1):64–9. [PubMed: 12074740]
183.
Taillandier S, Olesen JB, Clementy N, et al. Prognosis in Patients with Atrial Fibrillation and CHA(2) DS(2)-VASc Score = 0 in a Community-Based Cohort Study. J Cardiovasc Electrophysiol. 2012;23(7):708–13. [PubMed: 22268375]
184.
Yang YN, Yin WH, Feng AN, et al. Low-intensity warfarin therapy for the prevention of stroke in patients with high-risk nonvalvular atrial fibrillation. Acta Cardiologica Sinica. 2011;27(3):158–65.
185.
Cafolla A, Campanelli M, Baldacci E, et al. Oral anticoagulant therapy in Italian patients 80 yr of age or older with atrial fibrillation: A pilot study of low vs. standard PT/INR targets. Eur J Haematol. 2012;89(1):81–6. [PubMed: 22519759]
186.
Sam C, Massaro JM, D’Agostino RB Sr, et al. Warfarin and aspirin use and the predictors of major bleeding complications in atrial fibrillation (the Framingham Heart Study) Am J Cardiol. 2004;94(7):947–51. [PubMed: 15464686]
187.
Oldgren J, Alings M, Darius H, et al. Risks for Stroke, Bleeding, and Death in Patients With Atrial Fibrillation Receiving Dabigatran or Warfarin in Relation to the CHADS2 Score: A Subgroup Analysis of the RE-LY Trial. Ann Intern Med. 2011;155(10):660–7. [PubMed: 22084332]
188.
Fox KA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011;32(19):2387–94. [PubMed: 21873708]
189.
Hobbs FD, Roalfe AK, Lip GY, et al. Performance of stroke risk scores in older people with atrial fibrillation not taking warfarin: comparative cohort study from BAFTA trial. BMJ. 2011;342:d3653. [PMC free article: PMC3121229] [PubMed: 21700651]
190.
Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123(21):2363–72. [PubMed: 21576658]
191.
Lane DA, Kamphuisen PW, Minini P, et al. Bleeding risk in patients with atrial fibrillation: the AMADEUS study. Chest. 2011;140(1):146–55. [PubMed: 21415134]
192.
Nagarakanti R, Ezekowitz MD, Oldgren J, et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation. 2011;123(2):131–6. [PubMed: 21200007]
193.
Diener HC, Connolly SJ, Ezekowitz MD, et al. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol. 2010;9(12):1157–63. [PubMed: 21059484]
194.
Healey JS, Hart RG, Pogue J, et al. Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W) Stroke. 2008;39(5):1482–6. [PubMed: 18323500]
195.
Hohnloser SH, Pajitnev D, Pogue J, et al. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy. J Am Coll Cardiol. 2007;50(22):2156–61. [PubMed: 18036454]
196.
Hohnloser SH, Oldgren J, Yang S, et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation. 2012;125(5):669–76. [PubMed: 22215856]
197.
Hankey GJ, Patel MR, Stevens SR, et al. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol. 2012;11(4):315–22. [PubMed: 22402056]
198.
Lawrence J, Pogue J, Synhorst D, et al. Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. Lancet Neurol. 2012;11(3):225–31. [PubMed: 22305462]
199.
Easton JD, Lopes RD, Bahit MC, et al. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol. 2012;11(6):503–11. [PubMed: 22572202]
200.
Eikelboom JW, Connolly SJ, Gao P, et al. Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease. J Stroke Cerebrovasc Dis. 2012;21(6):429–35. [PubMed: 22818021]
201.
Hart RG, Diener HC, Yang S, et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke. 2012;43(6):1511–7. [PubMed: 22492518]
202.
Lopes RD, Al-Khatib SM, Wallentin L, et al. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. Lancet. 2012 [PubMed: 23036896]
203.
Hohnloser SH, Hijazi Z, Thomas L, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2012 [PubMed: 22933567]
204.
Ruff CT, Giugliano RP, Antman EM, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48) Am Heart J. 2010;160(4):635–41. [PubMed: 20934556]
205.
Maegdefessel L, Schlitt A, Faerber J, et al. Anticoagulant and/or antiplatelet treatment in patients with atrial fibrillation after percutaneous coronary intervention. A single-center experience. Med Klin (Munich) 2008;103(9):628–32. [PubMed: 18813885]
206.
Manzano-Fernandez S, Pastor FJ, Marin F, et al. Increased major bleeding complications related to triple antithrombotic therapy usage in patients with atrial fibrillation undergoing percutaneous coronary artery stenting. Chest. 2008;134(3):559–67. [PubMed: 18641090]
207.
Ruiz-Nodar JM, Marin F, Hurtado JA, et al. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. J Am Coll Cardiol. 2008;51(8):818–25. [PubMed: 18294566]
208.
Saad EB, Costa IP, Costa RE, et al. Safety of ablation for atrial fibrillation with therapeutic INR: comparison with transition to low-molecular-weight heparin. Arq Bras Cardiol. 2011;97(4):289–96. [PubMed: 21861038]
209.
Kwak JJ, Pak HN, Jang JK, et al. Safety and convenience of continuous warfarin strategy during the periprocedural period in patients who underwent catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol. 2010;21(6):620–5. [PubMed: 20039992]
210.
Hammerstingl C, Schmitz A, Fimmers R, et al. Bridging of chronic oral anticoagulation with enoxaparin in patients with atrial fibrillation: results from the prospective BRAVE registry. Cardiovasc Ther. 2009;27(4):230–8. [PubMed: 19903186]
211.
Wazni OM, Beheiry S, Fahmy T, et al. Atrial fibrillation ablation in patients with therapeutic international normalized ratio: comparison of strategies of anticoagulation management in the periprocedural period. Circulation. 2007;116(22):2531–4. [PubMed: 17998456]
212.
Bunch TJ, Crandall BG, Weiss JP, et al. Warfarin is not needed in low-risk patients following atrial fibrillation ablation procedures. J Cardiovasc Electrophysiol. 2009;20(9):988–93. [PubMed: 19473299]
213.
Lahtela H, Rubboli A, Schlitt A, et al. Heparin Bridging vs. Uninterrupted Oral Anticoagulation in Patients With Atrial Fibrillation Undergoing Coronary Artery Stenting. Circ J. 2012;76(6):1363–8. [PubMed: 22447005]
214.
Kiviniemi T, Karjalainen P, Pietila M, et al. Comparison of additional versus no additional heparin during therapeutic oral anticoagulation in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2012;110(1):30–5. [PubMed: 22464216]
215.
Snipelisky D, Kauffman C, Prussak K, et al. A comparison of bleeding complications post-ablation between warfarin and dabigatran. J Interv Card Electrophysiol. 2012 [PubMed: 22869389]
216.
Lakkireddy D, Reddy YM, Di Biase L, et al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol. 2012;59(13):1168–74. [PubMed: 22305113]
217.
Healey JS, Eikelboom J, Douketis J, et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation. 2012;126(3):343–8. [PubMed: 22700854]
218.
Ezekowitz MD, Connolly S, Parekh A, et al. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J. 2009;157(5):805–10. 10 e1–2. [PubMed: 19376304]
219.
Janssen Pharmaceuticals Inc. Prescribing information (package insert) for Xarelto®. [Accessed June 22, 2012]. Available at: www​.xareltohcp.com/sites​/default/files/pdf/xarelto_0.pdf.
220.
Boehringer Ingelheim Pharmaceuticals, Inc. Prescribing information (package insert) for Pradaxa®. [Accessed June 22, 2012]. Available at: http://bidocs​.boehringer-ingelheim​.com/BIWebAccess​/ViewServlet​.ser?docBase=renetnt&folderPath=​/Prescribing%20Information​/PIs/Pradaxa/Pradaxa.pdf.
221.
Dentali F, Riva N, Crowther M, et al. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation. 2012;126(20):2381–91. [PubMed: 23071159]
222.
Robinson KA, Saldanha IJ, Mckoy NA. Frameworks for Determining Research Gaps During Systematic Reviews. Methods Future Research Needs Report No. 2. Rockville, MD: Agency for Healthcare Research and Quality; Jun, 2011. (Prepared by the Johns Hopkins University Evidence-based Practice Center under Contract No. HHSA 290-2007-10061-I.) AHRQ Publication No. 11-EHC043-EF. Available at www​.effectivehealthcare​.ahrq.gov/reports/final.cfm.
Cover of Stroke Prevention in Atrial Fibrillation
Stroke Prevention in Atrial Fibrillation [Internet].
Comparative Effectiveness Reviews, No. 123.
Lopes RD, Crowley MJ, Shah BR, et al.

AHRQ (US Agency for Healthcare Research and Quality)

PubMed Health Blog...

read all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...